A comprehensive analysis of real-world patient data reveals that semaglutide, the active ingredient in the widely used weight loss drug Wegovy and diabetes medication Ozempic, is associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare but vision-threatening condition that can cause sudden, painless vision loss. While the absolute risk is low, the finding underscores the importance of awareness among patients and clinicians as these medications continue to gain popularity for both diabetes management and weight loss.

Researchers from multiple institutions conducted a systematic review and meta-analysis of observational studies comparing patients with type 2 diabetes who took semaglutide to those receiving other glucose-lowering treatments. The analysis included five primary studies and seven additional studies for sensitivity testing, examining data from January 2023 through November 2025. The team used rigorous methodology to assess study quality and certainty of evidence according to established medical standards.

What Is NAION and Why Should Semaglutide Users Care?

NAION is a rare eye condition in which blood flow to the optic nerve becomes blocked, leading to sudden vision loss that is often permanent. The condition typically develops without warning and causes no pain, making it particularly dangerous because patients may not seek immediate care. As semaglutide's use has expanded dramatically for weight loss and diabetes management, case reports began surfacing describing patients who developed NAION while taking the drug, prompting researchers to investigate whether a true association exists.

The meta-analysis found that semaglutide use was associated with a significantly increased hazard of NAION compared with other glucose-lowering regimens. Specifically, patients taking semaglutide faced approximately 2.17 times the risk of developing NAION compared to those on other diabetes medications, a statistically significant difference. When researchers compared semaglutide users to those taking other GLP-1 receptor agonists (a class of drugs that work similarly), the risk remained elevated at 1.96 to 2.13 times higher.

However, translating this relative risk into real-world numbers reveals a more reassuring picture. The absolute risk of developing NAION among semaglutide users is approximately 0.014%, which corresponds to roughly one additional case of NAION per 7,000 patients treated annually. This means that while the relative risk is doubled, the actual number of people affected remains very small. The European Medicines Agency and the World Health Organization have classified NAION as a "very rare" side effect of semaglutide, affecting up to 1 in 10,000 users per year.

How to Protect Your Vision While Taking GLP-1 Medications

• Monitor for sudden vision changes: If you experience any sudden, painless vision loss or changes in your eyesight while taking semaglutide, contact your eye doctor immediately. Early detection and reporting are critical, as NAION develops suddenly and can cause permanent damage.
• Inform your healthcare providers: Tell both your primary care doctor and eye doctor that you are taking semaglutide or other GLP-1 medications. This ensures they can monitor you appropriately and recognize any potential warning signs during routine eye exams.
• Discuss baseline eye health: If you have existing risk factors for optic neuropathies, such as a history of high blood pressure, diabetes, or previous eye problems, discuss these with your doctor before starting semaglutide to assess your individual risk profile.
• Schedule regular eye exams: Maintain routine eye care appointments while taking these medications. Your eye doctor can establish a baseline and monitor for any changes that might indicate developing problems.

The research team emphasized that while these findings support current recommendations to discontinue semaglutide in patients diagnosed with NAION, the certainty of the available evidence is low. The studies included in the analysis relied on retrospective, registry-based designs using diagnostic codes to identify NAION cases, which can introduce misclassification and confounding. The researchers graded the overall certainty of evidence as low to very low, meaning more high-quality, prospective studies are needed to confirm these results and better identify individuals at greatest risk.

What Do Broader Safety Concerns Tell Us About These Medications?

The NAION finding is one of several safety considerations emerging as GLP-1 medications like semaglutide and tirzepatide gain widespread use. A comprehensive review from the National Center for Health Research highlights multiple rare but serious concerns that patients should understand. The most common side effects remain gastrointestinal, including nausea and diarrhea, which lead many patients to stop taking these drugs within months. However, more serious potential adverse effects have been documented in clinical trials and real-world use.

Beyond vision problems, documented concerns include inflammation of the pancreas, gallbladder problems, low blood sugar, kidney problems, serious allergic reactions, increased heart rate, and depression or thoughts of suicide. Additionally, GLP-1 drugs carry an FDA warning about a possible connection to thyroid cancer based on animal studies, though evidence in humans remains mixed. A large 2025 study by Novo Nordisk, the manufacturer of Wegovy and Ozempic, analyzed data from over 100,000 people in clinical trials and found no increased rate of thyroid cancer compared to those on other medications.

Bone health represents another emerging concern. A 2026 study of over 146,000 U.S. adults with obesity and type 2 diabetes followed for five years found that approximately 4 out of every 100 people taking GLP-1 drugs developed osteoporosis, compared to about 3 out of 100 not taking the drugs. While this represents a small difference, it suggests that patients on these medications should prioritize bone health through adequate nutrition, exercise, and periodic bone density screening.

Another practical consideration involves medical procedures. Since GLP-1 drugs slow stomach emptying, patients should discuss their medication with their surgeon before any scheduled surgery or procedure. Food remaining in the stomach during anesthesia can be dangerous, as it may enter the lungs. Switching to clear liquids the day before surgery may help prevent this complication.

The findings about NAION and other safety concerns do not mean semaglutide and similar medications are unsafe for everyone. Rather, they highlight the importance of informed decision-making and close medical supervision. Patients considering these drugs should discuss their individual risk factors, baseline health status, and the potential benefits and risks with their healthcare providers. For those already taking semaglutide, the key is awareness and prompt reporting of any unusual symptoms, particularly sudden vision changes, to ensure early intervention if problems develop.

As these medications continue to be used by millions of people worldwide for both diabetes management and weight loss, ongoing research and surveillance remain essential. The researchers called for more high-quality, prospective studies employing standardized diagnostic criteria to clarify the association between semaglutide and NAION and to better identify and protect individuals at greatest risk.